Product Summary
Finerenone (BAY 94-8862) CAS 1050477-31-0 Premium Quality Pharmaceutical Compound Factory-direct high purity Finerenone (BAY 94-8862) with CAS number 1050477-31-0, available at competitive discount pricing while maintaining exceptional quality standards. ITEMS SPECIFICATION Appearance White to ...
High Purity 99% Finerenone (BAY 94-8862) CAS 1050477-31-0 with GMP and DMF
Basic Properties
Trading Properties
High Purity Finerenone
,Discount Price BAY 94-8862
,Best Quality CAS 1050477-31-0
Factory-direct high purity Finerenone (BAY 94-8862) with CAS number 1050477-31-0, available at competitive discount pricing while maintaining exceptional quality standards.
| ITEMS | SPECIFICATION |
|---|---|
| Appearance | White to yellow powder |
| Assay | 98.0%~102.0% |
| Identification | Meets the requirements |
| Water | ≤0.5% |
| Related Substances | ZEN2035-07 ≤ 0.15% |
| ZEN2035-0902 ≤ 0.15% | |
| ZEN2035-0903 ≤ 0.15% | |
| Any individual unspecified impurity ≤ 0.10% | |
| Total impurities ≤ 0.5% | |
| Isomer | ZEN2035-0904 ≤ 0.15% |
| Residual Solvents | Methanol ≤ 0.3% |
| Eethanol ≤ 0.5% | |
| Acetonitrile ≤ 0.041% | |
| Dichloromethane ≤ 0.06% | |
| Tetrahydrofuran ≤ 0.072% | |
| Toluene ≤ 0.089% | |
| o-xylene ≤ 0.0217% | |
| Triethyiamine ≤ 0.5% | |
| N,N-Dimethylacetamide ≤ 0.109% | |
| Residue on Ignition | ≤ 0.2% |
| Microbial Limit | Aerobic Bacteria Count ≤ 103cfu/g |
| The total number of molds and yeasts ≤ 102cfu/g | |
| E.coli: Negative | |
| Particle Size Distribution | D90:7.504 For reference only |
| Standard | In-house |
- High purity pharmaceutical grade compound
- CAS: 1050477-31-0
- Also known as BAY 94-8862
- Factory direct pricing with discounts available
- Consistent quality assurance
-
- Diabetic Kidney Disease (DKD): Approved in the US (2021) and EU (2022) to reduce the risk of kidney failure, eGFR decline, and cardiovascular events in adults with T2D and CKD (eGFR 25-75 mL/min/1.73 m² with albuminuria).
- Heart Failure (HF): Under priority review by the FDA for treating adults with HF and left ventricular ejection fraction (LVEF) ≥40% (HFmrEF/HFpEF), based on Phase III FINEARTS-HF trial data showing reduced cardiovascular mortality and hospitalization.
- Chronic Kidney Disease (CKD): Investigated in non-diabetic populations (FIND-CKD trial) to assess efficacy in broader CKD cohorts beyond T2D.
- Anti-fibrotic and Anti-inflammatory: Blocks MR-induced profibrotic gene transcription and inflammatory cytokine release in renal and cardiac tissues, slowing disease progression.
- Cardiorenal Protection: Lowers urinary albumin-to-creatinine ratio (UACR) and stabilizes eGFR in DKD, while reducing cardiovascular events (e.g., heart failure hospitalization, myocardial infarction) in HFmrEF/HFpEF.
- Improved Safety Profile: Selective MR antagonism and non-steroidal structure reduce hyperkalemia risk.
-
Ri found it in Bovita, and bough, amazing.
-
Jgood discount for me,thanks Bovita
-
SI have bought 3 times, very good
Please use our online inquiry contact form below if you have any questions, our team will get back to you as soon as possible.